In triple-negative breast cancer, the simultaneous targeted delivery of hyaluronidase and TGF-β siRNA modified the tumor microenvironment, effectively enhanced the T-cell-mediated anti-tumor immune response and enhanced the efficacy of PD-L1 inhibitors when used in combination, and brought hope to triple-negative breast cancer patients, who have the highest metastasis and recurrence rates [252]. This evidence concerns the gene TGFB1 and triple-negative breast carcinoma.